Interleukin-17 is required for control of chronic lung infection caused by Pseudomonas aeruginosa

Infection and Immunity

Volumn 84, Issue 12, 2016, Pages 3507-3516

  Bayes, Hannah K ^a   Ritchie, Neil D ^a   Evans, Thomas J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; INTERLEUKIN 17; IL17R PROTEIN, MOUSE; INTERLEUKIN 17 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; CD4+ T LYMPHOCYTE; CHRONIC LUNG DISEASE; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOCHEMISTRY; IMMUNOGLOBULIN PRODUCTION; LUNG FIBROSIS; LUNG HOMOGENATE; LUNG INFECTION; LYMPHOID CELL; MEDIASTINUM LYMPH NODE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEQUENCE ANALYSIS; TH17 CELL; ANIMAL; B LYMPHOCYTE; BACTERIAL PNEUMONIA; CELLULAR IMMUNITY; CHRONIC DISEASE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; METABOLISM; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; B-LYMPHOCYTES; CHRONIC DISEASE; IMMUNITY, CELLULAR; INTERLEUKIN-17; LUNG; MICE; MICE, KNOCKOUT; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECEPTORS, INTERLEUKIN-17;

EID: 85002808968     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00717-16     Document Type: Article

References (48)

1. Hoiby N, Frederiksen B, Pressler T. 2005. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4(Suppl 2):S49-S54. http://dx.doi.org/10.1016/j.jcf.2005.05.018
2. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Hoiby N, Molin S. 2012. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol 10:841-851. http://dx.doi.org/10.1038/nrmicro2907
3. Nichols D, Chmiel J, Berger M. 2008. Chronic inflammation in the cystic fibrosis lung: alterations in inter-and intracellular signaling. Clin Rev Allergy Immunol 34:146-162. http://dx.doi.org/10.1007/s12016-007-8039-9
4. Iwakura Y, Nakae S, Saijo S, Ishigame H. 2008. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226:57-79. http://dx.doi.org/10.1111/j.1600-065X .2008.00699.x
5. Decraene A, Willems-Widyastuti A, Kasran A, De Boeck K, Bullens DM, Dupont LJ. 2010. Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable cystic fibrosis patients. Respir Res 11:177. http://dx.doi.org/10.1186/1465-9921-11-177
6. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, Pier GB. 2008. IL-17 is a critical component of vaccineinduced protection against lung infection by lipopolysaccharideheterologous strains of Pseudomonas aeruginosa. J Immunol 181:4965-4975. http://dx.doi.org/10.4049/jimmunol.181.7.4965
7. Aujla SJ, Dubin PJ, Kolls JK. 2007. Th17 cells and mucosal host defense. Semin Immunol 19:377-382. http://dx.doi.org/10.1016/j.smim.2007.10 .009
8. Dubin PJ, Kolls JK. 2007. Pseudomonas aeruginosa and the host pulmonary immune response. Expert Rev Respir Med 1:121-137. http://dx.doi .org/10.1586/17476348.1.1.121
9. Bayes HK, Bicknell S, MacGregor G, Evans TJ. 2014. T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS One 9:e90263. http://dx.doi.org/10.1371/journal .pone.0090263
10. Dubin PJ, McAllister F, Kolls JK. 2007. Is cystic fibrosis a TH17 disease? Inflamm Res 56:221-227. http://dx.doi.org/10.1007/s00011-007-6187-2
11. Liu J, Feng Y, Yang K, Li Q, Ye L, Han L, Wan H. 2011. Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice. FEMS Immunol Med Microbiol 61:179-188. http://dx .doi.org/10.1111/j.1574-695X.2010.00764.x
12. van Heeckeren A, Schluchter M. 2002. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim 36:291. http://dx.doi.org/10.1258/002367702320162405
13. Bayes HK, Ritchie ND, Irvine S, Evans TJ. A murine model of early Pseudomonas aeruginosa lung disease with transition to chronic infection. Sci Rep, in press
14. Hoffmann N, Rasmussen TB, Jensen PO, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK, Hoiby N. 2005. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 73:2504-2514. http://dx.doi.org/10.1128/IAI.73.4 .2504-2514.2005
15. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito JE, Bagby GJ, Nelson S, Charrier K, Peschon JJ, Kolls JK. 2001. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colonystimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194:519-527. http://dx.doi.org/10.1084/jem.194.4.519
16. Kitamura D, Roes J, Kuhn R, Rajewsky K. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350:423-426. http://dx.doi.org/10.1038/350423a0
17. Moser C, Jensen PO, Kobayashi O, Hougen HP, Song Z, Rygaard J, Kharazmi A, Høiby N. 2002. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol 127:206-213. http://dx .doi.org/10.1046/j.1365-2249.2002.01731.x
18. van Heeckeren AM, Schluchter MD. 2002. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim 36:291-312. http://dx .doi.org/10.1258/002367702320162405
19. Bragonzi A. 2010. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol 300:584-593. http://dx .doi.org/10.1016/j.ijmm.2010.08.012
20. Koch C. 2002. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 34:232-236. http://dx.doi.org/10.1002/ppul .10135
21. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964. http://dx .doi.org/10.1038/35023079
22. Norman A, Ciofu O, Amador CI, Hoiby N, Jelsbak L. 2016. Genome sequence of Pseudomonas aeruginosa strain DK1-NH57388A, a stable mucoid cystic fibrosis isolate. Genome Announc 4:e00008-16. http://dx .doi.org/10.1128/genomeA.00008-16
23. Rada B, Leto TL. 2013. Pyocyanin effects on respiratory epithelium: relevance in Pseudomonas aeruginosa airway infections. Trends Microbiol 21:73-81. http://dx.doi.org/10.1016/j.tim.2012.10.004
24. Bayes HK, Ritchie ND, Ward C, Corris PA, Brodlie M, Evans TJ. 30 June 2016. IL-22 exacerbates weight loss in a murine model of chronic pulmonary Pseudomonas aeruginosa infection. J Cyst Fibros. http://dx .doi.org/10.1016/j.jcf.2016.06.008
25. Gaffen SL. 2011. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 23:613-619. http://dx.doi.org/10.1016/j.coi.2011.07.006
26. Baumgarth N. 2011. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 11:34-46. http://dx.doi .org/10.1038/nri2901
27. Sonnenberg GF, Artis D. 2015. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med 21:698-708. http://dx.doi.org/10.1038/nm.3892
28. Artis D, Spits H. 2015. The biology of innate lymphoid cells. Nature 517:293-301. http://dx.doi.org/10.1038/nature14189
29. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE, Powrie F, Vivier E. 2013. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 13:145-149. http://dx.doi.org/10.1038/nri3365
30. Griffin DO, Rothstein TL. 2012. Human B1 cell frequency: isolation and analysis of human B1 cells. Front Immunol 3:122. http://dx.doi.org/10 .3389/fimmu.2012.00122
31. Weber GF, Chousterman BG, Hilgendorf I, Robbins CS, Theurl I, Gerhardt LM, Iwamoto Y, Quach TD, Ali M, Chen JW, Rothstein TL, Nahrendorf M, Weissleder R, Swirski FK. 2014. Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. J Exp Med 211:1243-1256. http://dx.doi.org/10.1084/jem.20131471
32. Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, Tiglao E, Figueiredo JL, Iwamoto Y, Theurl I, Gorbatov R, Waring MT, Chicoine AT, Mouded M, Pittet MJ, Nahrendorf M, Weissleder R, Swirski FK. 2012. Innate response activator B cells protect against microbial sepsis. Science 335:597-601. http://dx.doi.org/10.1126/science.1215173
33. Schwarzenberger P, Huang W, Ye P, Oliver P, Manuel M, Zhang Z, Bagby G, Nelson S, Kolls JK. 2000. Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J Immunol 164:4783-4789. http://dx.doi.org/10.4049/jimmunol.164.9.4783
34. Taylor PR, Leal SM, Jr, Sun Y, Pearlman E. 2014. Aspergillus and Fusarium corneal infections are regulated by Th17 cells and IL-17-producing neutrophils. J Immunol 192:3319-3327. http://dx.doi.org/10 .4049/jimmunol.1302235
35. Augustin DK, Heimer SR, Tam C, Li WY, Le Due JM, Evans DJ, Fleiszig SM. 2011. Role of defensins in corneal epithelial barrier function against Pseudomonas aeruginosa traversal. Infect Immun 79:595-605. http://dx .doi.org/10.1128/IAI.00854-10
36. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. 2002. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75-79. http://dx.doi.org/10 .1038/nm0102-75
37. von Burg N, Chappaz S, Baerenwaldt A, Horvath E, Bose Dasgupta S, Ashok D, Pieters J, Tacchini-Cottier F, Rolink A, Acha-Orbea H, Finke D. 2014. Activated group 3 innate lymphoid cells promote T-cellmediated immune responses. Proc Natl Acad Sci U S A 111:12835-12840. http://dx.doi.org/10.1073/pnas.1406908111
38. Goc J, Hepworth MR, Sonnenberg GF. 2016. Group 3 innate lymphoid cells: regulating host-commensal bacteria interactions in inflammation and cancer. Int Immunol 28:43-52. http://dx.doi.org/10.1093/intimm/dxv056
39. Mackley EC, Houston S, Marriott CL, Halford EE, Lucas B, Cerovic V, Filbey KJ, Maizels RM, Hepworth MR, Sonnenberg GF, Milling S, Withers DR. 2015. CCR7-dependent trafficking of RORgamma( ) ILCs creates a unique microenvironment within mucosal draining lymph nodes. Nat Commun 6:5862. http://dx.doi.org/10.1038/ncomms6862
40. Nathan C. 2006. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6:173-182. http://dx.doi.org/10.1038/nri1785
41. Bermejo DA, Jackson SW, Gorosito-Serran M, Acosta-Rodriguez EV, Amezcua-Vesely MC, Sather BD, Singh AK, Khim S, Mucci J, Liggitt D, Campetella O, Oukka M, Gruppi A, Rawlings DJ. 2013. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγt and Ahr that leads to IL-17 production by activated B cells. Nat Immunol 14:514-522. http://dx.doi.org/10.1038/ni.2569
42. Ansel KM, Harris RB, Cyster JG. 2002. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 16:67-76. http://dx.doi.org/10.1016/S1074-7613(01)00257-6
43. Choi YS, Baumgarth N. 2008. Dual role for B-1a cells in immunity to influenza virus infection. J Exp Med 205:3053-3064. http://dx.doi.org/10 .1084/jem.20080979
44. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, Hodgkin PD, Nutt SL. 2004. Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J Exp Med 200:967-977. http://dx.doi.org/10.1084/jem.20040973
45. Ha SA, Tsuji M, Suzuki K, Meek B, Yasuda N, Kaisho T, Fagarasan S. 2006. Regulation of B1 cell migration by signals through Toll-like receptors. J Exp Med 203:2541-2550. http://dx.doi.org/10.1084/jem.20061041
46. Rakhimova E, Wiehlmann L, Brauer AL, Sethi S, Murphy TF, Tummler B. 2009. Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. J Infect Dis 200:1928-1935. http://dx.doi.org/10 .1086/648404
47. Zoumot Z, Wilson R. 2010. Respiratory infection in noncystic fibrosis bronchiectasis. Curr Opin Infect Dis 23:165-170. http://dx.doi.org/10 .1097/QCO.0b013e328335af91
48. Johansen HK, Gotzsche PC. 2015. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2015(8):CD001399. http://dx.doi.org/10.1002/14651858.CD001399.pub4